
Candel Therapeutics Receives U.S. FDA Fast Track Designation for CAN-2409 to Treat Stage III/IV NSCLC Patients
Candel Therapeutics receives FDA's fast track designation for CAN-2409, a viral immunotherapy developed to improve survival in combination with valacyclovir and pembrolizumab to treat stage III/IV non ...